Kwality Pharmaceuticals Management

Management Kriterienprüfungen 3/4

Kwality Pharmaceuticals CEO ist Ramesh Arora , ernannt in Jan 2016, hat eine Amtszeit von 8.83 Jahren. besitzt direkt 26.9% der Aktien des Unternehmens, im Wert von ₹2.48B . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 8.8 Jahre bzw. 8.9 Jahre.

Wichtige Informationen

Ramesh Arora

Geschäftsführender

₹6.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	8.8yrs
Eigentum des Geschäftsführers	26.9%
Durchschnittliche Amtszeit des Managements	8.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	8.9yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Ramesh Arora (70 yo)

8.8yrs

Amtszeit

₹6,000,000

Vergütung

Mr. Ramesh Arora has been the Managing Director and Executive Director of Kwality Pharmaceuticals Limited since January 16, 2016 and May 4, 1983 respectively. Mr. Arora has more than 3 decades of experienc...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ramesh Arora	MD & Director	8.8yrs	₹6.00m	26.9% ₹ 2.5b
Aditya Arora	CFO & Whole Time Director	8.8yrs	₹4.20m	11.95% ₹ 1.1b
Ajay Arora	Whole Time Director	no data	₹6.00m	13.59% ₹ 1.3b
Anju Arora	Whole Time Director	no data	₹2.40m	1.31% ₹ 120.7m
Geeta Arora	Whole Time Director	no data	₹2.40m	1.07% ₹ 99.2m
Gurpreet Kaur	Company Secretary & Compliance Officer	5.3yrs	keine Daten	keine Daten
Shankar Dayal	Chief Domestic Sales Officer	no data	keine Daten	keine Daten

8.8yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: 539997Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (8.8 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ramesh Arora	MD & Director	41.5yrs	₹6.00m	26.9% ₹ 2.5b
Aditya Arora	CFO & Whole Time Director	9.1yrs	₹4.20m	11.95% ₹ 1.1b
Ajay Arora	Whole Time Director	29.3yrs	₹6.00m	13.59% ₹ 1.3b
Anju Arora	Whole Time Director	14.1yrs	₹2.40m	1.31% ₹ 120.7m
Geeta Arora	Whole Time Director	14.1yrs	₹2.40m	1.07% ₹ 99.2m
Kiran Verma	Non-Executive Independent Director	8.8yrs	₹180.00k	keine Daten
Pankaj Takkar	Non-Executive Independent Director	8.8yrs	₹108.00k	0.029% ₹ 2.7m
Ravi Singh	Non-Executive Independent Director	8.8yrs	₹20.00k	keine Daten
Kartik Kapur	Independent Director	3.8yrs	₹20.00k	keine Daten
Prashanth Vellanki	Non-Executive & Independent Director	1.7yrs	₹7.00k	keine Daten

8.9yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrener Vorstand: 539997Die Vorstandsmitglieder gelten als erfahren (8.9 Jahre durchschnittliche Amtszeit).

Kwality Pharmaceuticals Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 24, 2024

Insufficient new directors

Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

Less than half of directors are independent

Kwality Pharmaceuticals Limited Announces the Resignation of Sachin Seth as Non- Executive and Non Independent Director

Less than half of directors are independent

Recent updates

Second quarter 2025 earnings released: EPS: ₹8.15 (vs ₹5.99 in 2Q 2024)

Investor sentiment improves as stock rises 19%

Kwality Pharmaceuticals Limited to Report Q2, 2025 Results on Oct 30, 2024

New minor risk - Share price stability

Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 24, 2024

Investor sentiment improves as stock rises 28%

First quarter 2025 earnings released: EPS: ₹8.04 (vs ₹5.10 in 1Q 2024)

Kwality Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 10, 2024

Full year 2024 earnings released: EPS: ₹22.76 (vs ₹18.67 in FY 2023)

Kwality Pharmaceuticals Limited to Report Q4, 2024 Results on May 23, 2024

Investor sentiment improves as stock rises 17%

Third quarter 2024 earnings released: EPS: ₹7.39 (vs ₹6.82 in 3Q 2023)

Insufficient new directors

Kwality Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 06, 2024

Kwality Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 04, 2023

Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

First quarter 2024 earnings released: EPS: ₹5.10 (vs ₹9.99 in 1Q 2023)

Kwality Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 10, 2023

New minor risk - Share price stability

Full year 2023 earnings released: EPS: ₹18.16 (vs ₹116 in FY 2022)

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: EPS: ₹6.82 (vs ₹15.20 in 3Q 2022)

Investor sentiment improved over the past week

Less than half of directors are independent

Kwality Pharmaceuticals Limited Announces the Resignation of Sachin Seth as Non- Executive and Non Independent Director

Second quarter 2023 earnings released: EPS: ₹8.82 (vs ₹57.33 in 2Q 2022)

Investor sentiment improved over the past week

Kwality Pharmaceuticals Limited to Report Fiscal Year 2023 Results on May 30, 2023

Investor sentiment improved over the past week

First quarter 2023 earnings released

Kwality Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 13, 2022

Kwality Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023

Investor sentiment improved over the past week

Kwality Pharmaceuticals Limited to Report Fiscal Year 2022 Results on May 28, 2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

CFO & Whole Time Director recently bought ₹1.3m worth of stock

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First half 2022 earnings released: EPS ₹90.57 (vs ₹6.70 in 1H 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹14.60 (vs ₹8.02 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day high: ₹61.15

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: ₹49.00

Kwality Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 13, 2020

Kwality Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2020

Kwality Pharmaceuticals Limited to Report Second Half, 2020 Results on Jul 13, 2020

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter